Amicus, Inc.
Amicus, Inc., a leading player in the biotechnology sector, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2002, the company has made significant strides in developing innovative therapies for rare genetic disorders, particularly focusing on enzyme replacement therapies.
Amicus is renowned for its flagship product, Galafold, which offers a unique treatment approach for Fabry disease, setting it apart in the competitive landscape. With a commitment to advancing patient care, Amicus has achieved notable milestones, including successful clinical trials and strategic partnerships that enhance its market position. As a pioneer in the biopharmaceutical industry, Amicus, Inc. continues to drive progress in the treatment of complex diseases, solidifying its reputation as a trusted name in biotechnology.
Part of the Sustainability team at Amicus, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Reported emissions
No reported emissions data is available for Amicus, Inc. yet.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Amicus, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Amicus, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project